# **Tab 1**

# **Psychedelic-Assisted Therapy Protocols: The Provider’s Perspective**

The re-emergence of psychedelic substances in clinical psychiatry and structured therapeutic settings represents a profound paradigm shift in mental healthcare. Unlike traditional psychopharmacology, which relies on the chronic, daily administration of symptom-managing medications, psychedelic-assisted therapy (PAT) utilizes a highly limited number of acute dosing sessions embedded within an extensive, highly structured framework of preparatory and integrative psychotherapy.1 This modality posits that the therapeutic efficacy is not derived solely from the pharmacological action of compounds like psilocybin or 3,4-methylenedioxymethamphetamine (MDMA), but rather from the intricate interaction between the neurobiological effects of the medicine and the extra-pharmacological variables of "set" (the patient's mindset) and "setting" (the physical and interpersonal environment).3

From the perspective of the clinical provider, medical monitor, or licensed facilitator, administering psychedelic therapy is a highly demanding, meticulously choreographed clinical process. It requires a unique synthesis of medical vigilance, trauma-informed psychotherapeutic skill, and an advanced capacity to provide non-directive, empathetic support during profoundly altered states of consciousness.5 Whether operating under the rigorous strictures of United States Food and Drug Administration (FDA) Phase 2 and Phase 3 clinical trials, or within newly established state-regulated frameworks such as the Oregon Psilocybin Services (OPS) Act, providers must adhere to exhaustive, multi-stage protocols.1

This report provides an exhaustive, sequential detailing of the psychedelic therapy treatment model from the provider's vantage point. It delineates the intricate mechanisms, clinical actions, ethical boundaries, and safety protocols required across the foundational phases of care: the foundational training of the provider, Phase 1 (Intake, Evaluation, and Preparation), Phase 2 (The Administration Session), and Phase 3 (Post-Treatment Integration), culminating in the cyclical continuation of subsequent treatment arcs.

## **The Foundation of Praxis: Provider Training, Credentialing, and Facility Readiness**

Before a provider ever makes first contact with a patient, an extensive architecture of professional training, ethical credentialing, and facility preparation must be established. The safe administration of consciousness-altering substances requires specialized competencies that diverge significantly from standard medical or psychological training.

In FDA-sanctioned clinical trials, such as the Phase 3 trials for MDMA-assisted therapy sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS), providers (often working in co-therapy dyads) must complete a rigorous, multi-stage training program. This program typically involves over 100 hours of didactic coursework, intensive virtual or in-person retreats, and the mandatory review of recorded therapy sessions.9 Providers are evaluated through a strict adherence and competence rating system, ensuring that their therapeutic interventions align perfectly with the standardized treatment manual.11 A unique and frequently debated component of some clinical training protocols involves the provider undergoing their own supervised psychedelic experience; many clinical supervisors argue that firsthand phenomenological knowledge of the altered state is essential for developing the deep empathetic attunement required to guide others through ontological shock or ego dissolution.10

In state-regulated models, such as the framework governed by the Oregon Health Authority (OHA), the barriers to entry and operational mandates are codified into administrative law. Oregon facilitators are not required to hold prior medical or clinical licensure—in fact, dual-licensed professionals (such as licensed clinical social workers or nurses) are explicitly prohibited from practicing within their traditional clinical scope while operating under their psilocybin facilitator license, to prevent the unlicensed practice of medicine within a non-medical framework.14 Instead, prospective facilitators must complete a state-approved training program encompassing a minimum of 120 to 150 hours of instruction.15 The curriculum mandates specific hours dedicated to historical and indigenous practices, cultural equity, pharmacology, core facilitation skills, and ethics.16 Furthermore, candidates must complete 40 hours of supervised practicum, pass a comprehensive state examination, and clear rigorous criminal background checks.15

The physical facility—referred to as the "Service Center" in state models or the "Clinical Site" in trial literature—must also undergo exhaustive preparation. Providers must secure local zoning approvals, such as a Land Use Compatibility Statement (LUCS), and ensure the facility is located at legally mandated distances from elementary and secondary schools (typically a 1,000-foot buffer, unless geographical barriers exist).19 The architectural layout must clearly demarcate "client administration areas" from "limited access areas" where the active compounds are stored.20 Security protocols are paramount; facilities must utilize fireproof safes weighing a minimum of 375 pounds for product storage, and maintain continuous, high-resolution video surveillance (minimum 1280 x 720 pixels at 10 frames per second) covering all ingress points and storage areas, with data retained for a minimum of 30 days.7

## **Phase 1: First Contact, Comprehensive Screening, and Intake**

The provider's direct clinical work begins with a rigorous evaluation process upon first contact. In both clinical trials and regulated state access models, this initial screening requires a delicate balance between expanding access to care and strictly adhering to contraindication protocols designed to prevent severe adverse events.23 Providers typically employ a battery of assessments to evaluate the patient's physical and psychiatric history, current medication regimen, and overall readiness for the psychological intensity of the psychedelic experience.25

### **Psychiatric and Somatic Evaluation**

Psychiatric exclusion criteria are stringent across almost all current therapeutic protocols. During the intake interview, providers must screen for a personal or family history (specifically first- or second-degree relatives) of psychotic disorders, including schizophrenia, schizoaffective disorder, and bipolar I or II disorder.23 The primary clinical concern is that the profound neurocognitive destabilization induced by classic psychedelics (such as psilocybin or LSD) could trigger latent psychosis, induce a manic episode, or cause enduring depersonalization.29 In advanced clinical trials, tools such as the Mini-International Neuropsychiatric Interview (MINI) or the Diagnostic Interview for Anxiety, Mood, and Obsessive-Compulsive and Related Neuropsychiatric Disorders (DIAMOND) are utilized to establish strict diagnostic boundaries.31 Furthermore, active suicidal ideation with intent (often measured via the Columbia-Suicide Severity Rating Scale), or a recent history of severe substance use disorders, frequently precludes participation in research trials, though state-regulated wellness models may evaluate these factors on a more individualized, harm-reduction basis.25

Medical and somatic screening is equally meticulous. Because both classic psychedelics and entactogens elicit sympathomimetic effects—specifically transient, dose-dependent elevations in blood pressure and heart rate—the cardiovascular integrity of the patient is a primary concern. Patients with uncontrolled hypertension (frequently defined as resting systolic \>140 mmHg or diastolic \>90 mmHg), severe cardiovascular disease, a history of ventricular arrhythmias, aneurysms, or a recent history of stroke are routinely excluded from treatment.23 Providers require baseline electrocardiograms (ECGs), comprehensive metabolic panels, complete blood counts, and hepatic function tests during the intake phase to ensure physiological stability and appropriate renal clearance capacities.25

### **Pharmacological Tapering and Contraindications**

Pharmacological interactions represent one of the most critical areas of provider oversight during the intake phase. The concurrent use of selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and monoamine oxidase inhibitors (MAOIs) presents complex clinical challenges. MAOIs are universally contraindicated due to the severe, potentially fatal risk of serotonin syndrome when combined with serotonergic psychedelics.23

SSRIs and SNRIs, through chronic administration, often down-regulate the 5-HT2A receptors, which are the primary binding sites for classic psychedelics. Consequently, these medications can significantly blunt the subjective and therapeutic effects of psilocybin.38 Providers generally require patients to undergo a supervised tapering process, ensuring they have been completely off serotonergic medications for at least five half-lives (often two to four weeks) prior to the dosing session to ensure receptor baseline.23 Notably, recent progressive trials investigating psilocybin as an adjunct to SSRIs suggest that co-administration might be safe and could bypass the destabilizing effects of antidepressant withdrawal, but tapering remains the gold standard in predominant protocols to ensure unimpeded pharmacological action.8

Furthermore, providers must assess for medications that inhibit the cytochrome P450 2D6 (CYP2D6) metabolic pathway. Strong CYP2D6 inhibitors can significantly increase the maximal concentration and total systemic exposure of substances like LSD, requiring providers to either exclude the patient or carefully adjust the targeted dose.39 Lithium is also universally contraindicated across all paradigms, even in state-regulated non-medical models, due to well-documented risks of inducing seizures, cardiac events, or severe dissociative episodes when combined with psychedelics.14

![][image1]

### **Establishing the Psychometric Baseline**

To objectively measure clinical outcomes and track the trajectory of the patient's psychological evolution, providers administer a comprehensive suite of psychometric evaluations during the final stages of the intake phase.40 These baseline measurements are vital for quantifying the severity of the presenting condition and establishing a statistical reference point for post-treatment comparisons.

For depressive disorders, tools such as the clinician-administered Montgomery-Åsberg Depression Rating Scale (MADRS), the Quick Inventory of Depressive Symptomatology (QIDS-SR16), and the Patient Health Questionnaire (PHQ-9) are standardly employed.33 In trauma-focused protocols, such as those utilizing MDMA for PTSD, the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) serves as the primary endpoint measure.23 Beyond symptom-specific scales, providers increasingly utilize assessments that measure broader psychological constructs hypothesized to be the underlying mechanisms of change in psychedelic therapy. The Acceptance and Action Questionnaire (AAQ-II) is frequently used to assess psychological flexibility—the patient's baseline ability to remain in contact with the present moment and endure negative emotions without resorting to experiential avoidance.40 Additionally, the Psychedelic Preparedness Scale (PPS) is emerging as a critical tool for providers to systematically assess an individual's practical, emotional, and psychophysical readiness for the journey, allowing the provider to identify specific domains that require fortification during the preparation sessions.45

| Assessment Tool | Primary Construct Measured | Utilization Timing by Provider | Clinical Objective |
| :---- | :---- | :---- | :---- |
| **MADRS / QIDS-SR16** | Depression Severity | Intake Baseline, Post-Treatment Follow-ups | Quantify disease burden and track longitudinal clinical efficacy of the intervention for mood disorders. |
| **CAPS-5** | PTSD Symptomatology | Intake Baseline, Post-Treatment Follow-ups | Serve as the primary efficacy endpoint for trauma-focused therapeutic protocols. |
| **AAQ-II** | Psychological Flexibility | Intake Baseline, Post-Treatment Follow-ups | Assess the patient's capacity to tolerate distress without utilizing experiential avoidance mechanisms. |
| **PPS** | Psychedelic Preparedness | Post-Intake, Pre-Dosing | Identify gaps in the patient's readiness, allowing the provider to tailor the preparatory psychotherapy phase. |

## **Phase 1: Preparatory Psychotherapy and the Construction of the Container**

Once medical and psychological clearance is officially achieved, the provider and patient transition into the preparatory psychotherapy phase. This process typically spans one to three dedicated sessions, totaling three to eight hours of clinical contact time, depending on the specific protocol and the half-life of the intended substance.8 The objective here is not to conduct deep, resolution-oriented trauma processing, but rather to construct a resilient "therapeutic container" capable of safely holding the psychological volatility of the upcoming dosing session.

### **Cultivating the Therapeutic Alliance**

Developing a profound therapeutic alliance is the absolute cornerstone of this phase.46 The patient must develop absolute trust in the provider, as the psychedelic state inherently involves profound emotional vulnerability, heightened suggestibility, and a temporary, pharmacologically induced dismantling of the ego's standard psychological defense mechanisms.3 Providers accomplish this by demonstrating an empathetic, non-judgmental presence, actively listening to the patient's life narrative, and exploring the specific etiology of their suffering.6 The provider assesses the patient's attachment style and interpersonal dynamics to anticipate how the patient might interact with the clinical team when their standard cognitive filters are removed.49

### **Psychoeducation and Expectation Management**

During preparation, providers engage in extensive psychoeducation. They map out the phenomenological landscape the patient is likely to encounter. Patients are explicitly informed that they may experience vivid visual and auditory alterations, profound shifts in the perception of time and space, the sudden surfacing of repressed autobiographical memories, and a spectrum of emotions ranging from exalted bliss to deep grief, paranoia, or terror.50

A central tenet imparted by the provider—highly utilized in MAPS MDMA protocols—is the concept of the "inner healing intelligence." Originating from transpersonal psychology, this concept suggests that the human psyche, much like the physical body's capacity to heal a laceration, possesses an innate, autonomous drive toward psychological wholeness and healing when placed in the proper conditions.1 The provider's role is carefully framed not as an active healer actively extracting pathology or directing the mind, but as an empathetic witness holding a safe space for the patient's own internal wisdom to unfold.46

Providers operating under protocols like the Yale Manual for Psilocybin-Assisted Therapy of Depression often integrate Acceptance and Commitment Therapy (ACT) frameworks during this preparatory window. Patients are taught that psychiatric distress is often rooted in "experiential avoidance"—the desperate, exhausting attempt to escape painful internal states.53 The provider instructs the patient to adopt an attitude of radical curiosity and acceptance toward whatever arises during the dosing session. To illustrate this, providers frequently utilize the "ski slope" metaphor: depression and trauma create deep cognitive ruts, so that thoughts automatically flow down the same negative pathways. The psychedelic medicine acts as a fresh coat of snow, temporarily flattening the energy landscape of the brain and providing the freedom to ski down entirely new paths.51 If terrifying imagery or somatic pain emerges, the patient is coached to "lean in" and explore the sensation, adopting the mantra to "trust, let go, and be open," rather than attempting to flee back to the familiar ruts.54

### **Ethical Contracting and Logistical Mandates**

The culmination of the preparatory phase involves meticulous logistical planning and rigid ethical boundary setting. In regulated models such as Oregon's, the provider is legally mandated to co-create a detailed, written "Safety and Support Plan" with the client.56 This document identifies potential idiosyncratic risks based on the patient's history, establishes emergency contacts, and maps out the client's existing external support networks.58 A transportation plan is formalized, strictly mandating that the patient will not drive themselves home after the profound cognitive alterations of the dosing session, relying instead on a pre-arranged proxy.60

Crucially, the provider establishes clear, dynamic consent regarding physical touch. Because the altered state severely diminishes a patient's capacity to provide ongoing, legally sound consent, agreements regarding touch must be explicitly established and documented beforehand.15 Providers clarify that any touch will be strictly non-sexual and utilized solely for somatic grounding and support—typically limited by protocol to holding a hand, or placing a hand on the shoulder or foot.14 Providers also explain how they will navigate the shifting landscape of consent during the session itself. Rather than using directive requests, providers are trained to use open-ended inquiries (e.g., asking "How would it feel if I placed my hand on your shoulder right now?" rather than a directive "Is it okay if I touch you?"), ensuring the patient maintains a sense of autonomy despite their vulnerable state.64

With the medical screening complete, the therapeutic alliance solidified, the psychometric baselines recorded, and the logistical boundaries firmly contracted, the provider and patient conclude Phase 1, fully primed for the pharmacological intervention.

## **Phase 2: The Dosing and Administration Session**

The administration session represents the crucible of psychedelic-assisted therapy. It is an intensive, uninterrupted clinical event—typically lasting between six to eight hours for classic psychedelics or MDMA—requiring the provider's absolute vigilance and emotional attunement.5 As the patient ingests the compound, the provider's primary directive shifts from active psychological investigation to environmental management, physiological monitoring, and non-directive support.

### **Designing the Milieu: Set, Setting, and Sensory Management**

The physical environment (the "setting") is systematically curated by the provider to minimize clinical sterility and maximize a sense of psychological safety, warmth, and aesthetic comfort.65 Adhering to emerging best practices, such as the ReSPCT (Reporting of Setting in Psychedelic Clinical Trials) guidelines, providers design spaces that purposefully resemble comfortable living rooms rather than sterile hospital wards.66

The room is typically centered around a comfortable futon, bed, or recliner where the patient will spend the vast majority of the session. In MAPS protocols, the arrangement is highly specified: the patient lies flat or slightly propped up, while two co-therapists sit in chairs positioned on either side of the patient, near the head.68 This specific spatial geometry fosters a sense of the patient having their own uninterrupted space to focus inward, while still allowing the providers to easily enact physical containment or offer supportive touch if required. Providers carefully control ambient factors: lighting is kept soft, warm, and adjustable to prevent visual overstimulation; temperature is closely monitored and modulated with blankets, as psychedelics frequently induce fluctuations in thermoregulation and diaphoresis; and necessary medical equipment is kept out of direct sight to prevent the induction of clinical anxiety or paranoia.4 Biophilic elements—such as living plants, natural textures, and nature-themed artwork—are frequently incorporated, as research indicates that connection to nature enhances the subjective quality of the psychedelic experience and grounds the patient.67

### **The Acoustic Architecture: The Wave Model of Music Curation**

Auditory stimulation is recognized within the clinical framework not merely as background ambiance, but as a primary conduit for the therapeutic process. Providers utilize carefully curated, pre-tested music playlists that act as an emotional guide, facilitating the patient's journey into and through the altered state.54 The selection of music is a highly technical aspect of the provider's role, generally structured around a pharmacokinetic "wave model" that mirrors the metabolic absorption, peak, and elimination of the administered substance.

The auditory protocol is typically divided into three distinct phases:

1. **Ascent and Onset:** As the medication begins to take effect (typically 20 to 60 minutes post-ingestion), the provider plays calm, melodic, and inviting music. This phase is designed to reduce anticipatory anxiety, lower physiological defenses, and assist the patient in surrendering conscious control.54  
2. **The Peak (Confrontation and Plateau):** Corresponding with the maximum blood plasma concentration of the drug, the music transitions to expansive, intense, and occasionally challenging orchestral or choral pieces.54 This phase is deliberately curated to evoke deep emotional resonance, pushing the patient toward confronting repressed trauma, grief, or facilitating transcendent, mystical-type experiences. As the peak stabilizes into a plateau, the music subtly shifts to softer, lyrical compositions that provide a sense of holding, affection, and safety.54  
3. **Descent and Re-entry:** As the acute pharmacological effects wane, the provider transitions the playlist to grounding, familiar, and comforting ambient sounds, aiding the patient in transitioning back to standard waking consciousness without jarring abruptness.54

Providers must constantly monitor the patient's physiological and emotional reactions to the music. If a patient exhibits signs of severe distress, the provider may ask if the discomfort is productive; if it is merely overwhelming, the provider adjusts the volume or skips to a more grounding track.54 Furthermore, lyrical music in the patient's native language is strictly avoided during the ascent and peak phases, as recognizable words can prematurely trigger analytical thought and semantic processing, pulling the patient out of the visceral, somatic experience.72

![][image2]

### **The Ritual of Administration and Non-Directive Support**

The administration session commences with a brief period of grounding. The provider reviews the previously established intentions, reaffirms the boundaries of the therapeutic container, and conducts baseline physiological checks.73 The medication is administered in a formalized, culturally respectful manner that acknowledges the gravity of the undertaking.8 Dosing protocols vary by substance and framework: current psilocybin trials frequently utilize a fixed oral dose of 25mg (eschewing older weight-based 0.3mg/kg models), while MDMA protocols often employ a split-dose strategy, administering an initial 80mg to 120mg capsule followed by a supplemental half-dose 1.5 to 2 hours later to prolong the therapeutic window.8

Once the medication is ingested, the patient is encouraged to recline, place an eye mask over their eyes, and don the high-fidelity headphones.78 This sensory deprivation strategy forces the patient's attention inward, eliminating external visual distractions and amplifying the internal cognitive and emotional cascade.46

From this point forward, the provider adopts a strictly non-directive stance. Unlike traditional cognitive behavioral therapy, where the clinician actively interprets, guides, or attempts to restructure the patient's narrative, the psychedelic facilitator practices "empathetic abiding presence".22 The provider acts as an anchor—a silent, vigilant guardian of the physical and psychological space.46 They do not initiate conversation, ask probing questions, or attempt to clinically analyze the chaotic, often symbolic visions the patient is experiencing.81

If the patient removes their eye mask to speak, the provider utilizes techniques of minimal encouragement. They reflect and validate the patient's statements without steering the trajectory of the thought.80 For example, if a patient describes a terrifying encounter with an internalized representation of their trauma, the provider does not attempt to dissect the metaphor. Instead, they offer reassuring, present-focused affirmations, reminding the patient that they are safe, that the physiological effects of the medicine are temporary, and encouraging them to return their focus inward with curiosity.81

### **Navigating the "Challenging Experience"**

One of the most critical responsibilities of the provider during Phase 2 is the management of adverse psychological reactions. In the lexicon of psychedelic therapy, the concept of a "bad trip" is fundamentally reframed as a "challenging experience".4 The destabilization of the brain's default mode network often results in the unearthing of repressed grief, intense paranoia, sensations of physical dissolution (ego death), and profound ontological fear.29

When a patient enters a state of acute panic or looping traumatic regression, the provider's intervention protocols are behavioral and somatic, rather than immediately pharmacological.87 The provider moves closer to the patient, modulating their tone to convey absolute calm and safety. They employ the pre-negotiated somatic tools, offering a hand to hold or placing a reassuring hand on the shoulder, providing a physical tether to consensus reality.55

The provider coaches the patient through the distress using the principles of acceptance established in Phase 1\. Instead of attempting to suppress the terrifying imagery or flee the anxiety, the patient is guided to breathe directly into the discomfort.53 Providers operate on the clinical understanding that these challenging periods are often the crucible in which the most profound therapeutic breakthroughs occur; resolving the conflict internally, rather than aborting it externally, builds enduring psychological resilience and structural neural changes.84 Pharmacological rescue interventions (such as the administration of benzodiazepines or antipsychotics) are maintained on-site as a last resort, utilized only if the patient becomes an unmanageable danger to themselves, attempts to flee the facility, or suffers a severe medical event.38

### **Clinical Monitoring and Discharge Protocols**

Throughout the duration of the session, the provider conducts discreet, periodic assessments of the patient's vital signs. In protocols involving cardiovascular stimulants like MDMA or high-dose psilocybin, blood pressure and heart rate are recorded at predetermined intervals (e.g., prior to dosing, every 30 minutes for the first two hours, and hourly thereafter) to ensure they remain below dangerous thresholds. Strict clinical cutoffs are maintained; for instance, if a patient exhibits a sustained systolic blood pressure over 200 mmHg or diastolic over 110 mmHg for more than 15 minutes, emergency medical transfer protocols are initiated.35 These checks are performed with minimal intrusion so as not to disrupt the patient's internal focus.74

As the pharmacological effects diminish—usually at the six-to-eight-hour mark—the patient gradually returns to baseline consciousness. The provider facilitates this re-entry, offering hydration and light nourishment.67 The provider engages in a gentle debriefing, allowing the patient to articulate their immediate impressions without forcing them into a rigid clinical framework or demanding immediate narrative coherence. Before discharge, the provider conducts a final assessment of physical coordination, gait steadiness, and mental status.74 Once deemed physiologically and psychologically safe, the patient is released into the care of their pre-arranged transportation proxy, with explicit instructions to rest, avoid strenuous mental or physical activity, and refrain from making major life decisions in the immediate aftermath.70

## **Phase 3: Post-Treatment Integration and Meaning-Making**

The resolution of the administration session marks the beginning of the most critical, yet frequently underestimated, component of the treatment protocol: Integration. The neuroplastic window opened by the psychedelic compound—often characterized by a sustained "afterglow" of cognitive flexibility and heightened synaptic connectivity—leaves the patient highly receptive to behavioral and cognitive restructuring.4 However, without structured provider intervention, the profound realizations achieved during the dosing session can rapidly evaporate as the brain reverts to its familiar, pathological default modes, leading to symptomatic relapse.94

### **The Architecture of Integration Sessions**

Integration typically comprises one to three dedicated psychotherapy sessions scheduled in the days and weeks immediately following the administration, generally beginning within the first 24 to 72 hours.20 The provider's role shifts back from a silent witness to an active, collaborative guide. The primary clinical objective is "meaning-making"—assisting the patient in translating the abstract, often ineffable symbolic visions of the psychedelic state into concrete, actionable changes in their daily life and interpersonal relationships.95

Providers utilize structured, open-ended inquiries to facilitate this translation without imposing their own biases.97 They prompt the patient to reflect on specific domains:

* What were the predominant emotional tones of the experience, and did any specific archetypes, memories, or somatic sensations manifest?  
* How do the epiphanies encountered relate to the initial therapeutic intentions established during Phase 1?  
* What specific, structural changes in relationships, career, or self-care are necessary to honor and sustain these new perspectives?

To anchor these fleeting insights, providers prescribe active integration homework. This often includes somatic practices (yoga, breathwork, and time in nature) to regulate the autonomic nervous system, as well as expressive arts and structured journaling to capture the nuances of the experience before they fade from memory.97

### **Mitigating Post-Acute Vulnerabilities**

The integration phase is not solely focused on maximizing positive outcomes; it is highly focused on risk mitigation. Providers must monitor for delayed adverse reactions, which can manifest as extended periods of depersonalization, derealization, social disconnection, or existential confusion—often referred to as "ontological shock".86 Patients who experienced terrifying or chaotic visions during Phase 2 without achieving a sense of resolution or emotional breakthrough may exhibit heightened anxiety or depressive rebound in the days following the session.79

Providers must delicately deconstruct these challenging narratives. Utilizing therapies such as EMDR (Eye Movement Desensitization and Reprocessing) or somatic experiencing, the provider helps the patient reframe the distress as a necessary unearthing of repressed psychological material rather than a regression or a "failed" treatment, essentially processing the psychedelic experience itself as a deeply potent memory.84

Furthermore, providers must actively guard against "spiritual bypassing" or ego-inflation. Patients who experience profound mystical unity or ego dissolution may return with a sense of messianic grandiosity or a belief that they are fundamentally "cured," leading them to prematurely abandon necessary ongoing psychiatric care or boundary structures.102 The provider grounds the patient, emphasizing that the psychedelic experience is a catalyst for the real work of recovery, not the final destination.81

### **Psychometric Evaluation of Outcomes**

During the integration phase, providers deploy a secondary battery of psychometric tools to capture the subjective qualities of the psychedelic experience and track longitudinal clinical efficacy.14

To quantify the acute subjective effects, providers administer retrospective questionnaires such as the Mystical Experience Questionnaire (MEQ-30), which evaluates dimensions of ineffability, positive mood, and transcendence of time and space.35 The Ego Dissolution Inventory (EDI) measures the disintegration of the self-referential construct, while the Emotional Breakthrough Inventory (EBI) assesses the degree to which the patient successfully confronted and resolved difficult emotions.40 The Challenging Experience Questionnaire (CEQ) is utilized to map the intensity of fear, grief, or physical distress encountered.35 Recently, the Integration Engagement Scale (IES) and Experienced Integration Scale (EIS) have been adopted to measure the patient's behavioral and intrapsychic success in embedding the experience into their daily lives.102

Simultaneously, the provider re-administers the clinical baseline tools (e.g., MADRS, CAPS-5) at specific endpoints (such as one week, four weeks, and six months post-treatment) to objectively measure the reduction in pathological symptoms and justify the continuation or cessation of the treatment protocol.42

## **The Iterative Cycle: Dose Escalation and Returning to Phase 2**

Psychedelic-assisted therapy is rarely a single-event intervention. Most modern clinical protocols, including those for MDMA and psilocybin, utilize a multi-dose sequence to maximize and sustain therapeutic benefits.8 A standard trajectory involves an initial dosing session, followed by the integration period, which then seamlessly transitions into preparation for a subsequent dosing session, typically spaced two to four weeks later.8

This cyclical approach requires the provider to continually iterate upon the therapeutic container. The data gathered during the first integration phase directly informs the strategy for the second administration. If a patient struggled with intense somatic anxiety or "looping" thoughts during the first session, the provider might dedicate the subsequent preparation sessions to rehearsing specialized breathwork, grounding techniques, or utilizing EMDR to desensitize the patient to the dysregulation they experienced.107

Furthermore, the provider utilizes the psychometric data from the first session to make critical dose-escalation decisions. In adaptive trial designs, the subjective intensity of the first dose dictates the volume of the second. If a patient's MEQ-30 scores indicate a sub-optimal subjective experience (e.g., failing to reach the 60% threshold across subscales required for a "complete mystical experience"), and no severe adverse medical events were noted, the provider, in consultation with the medical monitor, will likely escalate the dosage for the second session. For example, a psilocybin protocol might escalate from an initial 25mg to 30mg or 40mg, or an MDMA protocol might escalate from an 80mg base dose to a 120mg base dose.8 In early-phase exploratory trials (such as Phase 1 trials assessing pharmacokinetics), this dose escalation is highly regimented to establish basic safety ceilings.30

This iterative cycle—Preparation, Administration, Integration—acts as an upward spiral. Each subsequent dosing session benefits from the strengthened therapeutic alliance, the patient's increased familiarity with navigating altered states, and the targeted refinement of intentions based on previous revelations.

## **Conclusion**

The administration of psychedelic-assisted therapy demands a radical expansion of traditional psychiatric and psychological skill sets. Providers must operate at the perilous intersection of rigorous medical monitoring and profound, intuitive space-holding. They are required to meticulously screen for complex physiological and pharmacological contraindications, design highly controlled yet emotionally resonant environments, and navigate the volatile, unpredictable terrain of the human psyche under the influence of powerful neuro-catalysts.

The success of this modality does not rest on the pharmacological mechanism of the drug alone. It relies entirely on the provider's ability to forge an unbreakable therapeutic alliance, to offer unwavering non-directive support in the face of a patient's deepest traumas, and to skillfully weave the chaotic insights of the psychedelic state into the functional fabric of the patient's daily life. As these protocols transition from the tightly controlled environments of Phase 3 clinical trials into broader, state-regulated public access models, the standardization, rigorous training, and ethical fortitude of the providers will be the ultimate determinants of the safety, efficacy, and legitimacy of this new frontier in mental health treatment.

#### **Works cited**

1. The conceptual framework for the therapeutic approach used in, accessed February 17, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11571099/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11571099/)  
2. Culturally informed research design issues in a study for MDMA, accessed February 17, 2026, [https://akjournals.com/downloadpdf/view/journals/2054/4/1/article-p40.pdf](https://akjournals.com/downloadpdf/view/journals/2054/4/1/article-p40.pdf)  
3. Psilocybin-Assisted suppoRtive psychoTherapy IN the ... \- BMJ Open, accessed February 17, 2026, [https://bmjopen.bmj.com/content/15/4/e095992](https://bmjopen.bmj.com/content/15/4/e095992)  
4. Psychedelic-assisted therapy: An overview for the internist, accessed February 17, 2026, [https://www.ccjm.org/content/ccjom/92/3/171.full.pdf](https://www.ccjm.org/content/ccjom/92/3/171.full.pdf)  
5. The conceptual framework for the therapeutic approach used in, accessed February 17, 2026, [https://www.frontiersin.org/journals/psychology/articles/10.3389/fpsyg.2024.1427531/full](https://www.frontiersin.org/journals/psychology/articles/10.3389/fpsyg.2024.1427531/full)  
6. 5fb9cd79ec09452ffd8ec945 \- Blossom \- Protocol v0.3 | Psilocybin, accessed February 17, 2026, [https://www.scribd.com/document/866917196/5fb9cd79ec09452ffd8ec945-Blossom-Protocol-v0-3](https://www.scribd.com/document/866917196/5fb9cd79ec09452ffd8ec945-Blossom-Protocol-v0-3)  
7. Division 333 PSILOCYBIN \- Oregon Secretary of State, accessed February 17, 2026, [https://secure.sos.state.or.us/oard/displayDivisionRules.action?selectedDivision=7102](https://secure.sos.state.or.us/oard/displayDivisionRules.action?selectedDivision=7102)  
8. NCT06407635 | A Study of Psilocybin for PTSD \- ClinicalTrials.gov, accessed February 17, 2026, [https://clinicaltrials.gov/study/NCT06407635](https://clinicaltrials.gov/study/NCT06407635)  
9. MDMA-Assisted Therapy for PTSD \- Bessel van der Kolk, accessed February 17, 2026, [https://www.besselvanderkolk.com/maps](https://www.besselvanderkolk.com/maps)  
10. Training for MDMA-based psychotherapy for PTSD, accessed February 17, 2026, [https://is-sp.org/en/trainings/training-for-mdma-based-psychotherapy-for-ptsd/](https://is-sp.org/en/trainings/training-for-mdma-based-psychotherapy-for-ptsd/)  
11. Treatment Manual: MDMA-Assisted Therapy for PTSD \- MAPS.org, accessed February 17, 2026, [https://maps.org/mdma/mdma-resources/treatment-manual-mdma-assisted-psychotherapy-for-ptsd/](https://maps.org/mdma/mdma-resources/treatment-manual-mdma-assisted-psychotherapy-for-ptsd/)  
12. MDMA Therapy Adherence Manual | PDF | Psychotherapy \- Scribd, accessed February 17, 2026, [https://www.scribd.com/document/346102894/MDMA-Assisted-Psychotherapy-Therapist-Adherence-and-Competence-Ratings-Manual](https://www.scribd.com/document/346102894/MDMA-Assisted-Psychotherapy-Therapist-Adherence-and-Competence-Ratings-Manual)  
13. Psilocybin Experiential Therapist Training \- medRxiv.org, accessed February 17, 2026, [https://www.medrxiv.org/content/10.1101/2025.11.15.25340324v1.full.pdf](https://www.medrxiv.org/content/10.1101/2025.11.15.25340324v1.full.pdf)  
14. Summary Analysis of Oregon Psilocybin Services Draft Rules, accessed February 17, 2026, [https://www.brainfutures.org/wp-content/uploads/2023/06/Harbin-Analysis-of-Oregon-Draft-Regulations-Nov-21-2022-FINAL.pdf](https://www.brainfutures.org/wp-content/uploads/2023/06/Harbin-Analysis-of-Oregon-Draft-Regulations-Nov-21-2022-FINAL.pdf)  
15. Natural Medicine Advisory Bulletin \#8.1: Recommendation Round-up, accessed February 17, 2026, [https://psychedelicalpha.com/news/natural-medicine-advisory-bulletin-8-1-recommendation-round-up](https://psychedelicalpha.com/news/natural-medicine-advisory-bulletin-8-1-recommendation-round-up)  
16. The Perilous Policy of Oregon's Psilocybin Services, accessed February 17, 2026, [https://jaapl.org/content/51/2/160](https://jaapl.org/content/51/2/160)  
17. Facilitator Training Program Curriculum Worksheet | Oregon.gov, accessed February 17, 2026, [https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Documents/TP-Curriculum-Worksheet.pdf](https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Documents/TP-Curriculum-Worksheet.pdf)  
18. Oregon Psilocybin Facilitator License Essential Guide \- Catalyst BC, accessed February 17, 2026, [https://catalyst-bc.com/oregon-psilocybin-facilitator-license-essential-guide/](https://catalyst-bc.com/oregon-psilocybin-facilitator-license-essential-guide/)  
19. Psilocybin Facilitator License Application Guide \- Oregon.gov, accessed February 17, 2026, [https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Documents/Facilitator-License-Application-Guide-ONLINE.pdf](https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Documents/Facilitator-License-Application-Guide-ONLINE.pdf)  
20. Oregon Psilocybin Service Center License Essential Guide, accessed February 17, 2026, [https://catalyst-bc.com/oregon-psilocybin-service-center-license-essential-guide/](https://catalyst-bc.com/oregon-psilocybin-service-center-license-essential-guide/)  
21. 333-333 PROPOSED Rules \- Oregon.gov, accessed February 17, 2026, [https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Documents/333-333-PROPOSED-Rules.pdf](https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Documents/333-333-PROPOSED-Rules.pdf)  
22. Facilitator Conduct and Psilocybin Services 1 \- Oregon.gov, accessed February 17, 2026, [https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Documents/Draft-Rules-RAC-3-Facilitator-Conduct-Preparation-Administration-and-Integration-Sessions.pdf](https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Documents/Draft-Rules-RAC-3-Facilitator-Conduct-Preparation-Administration-and-Integration-Sessions.pdf)  
23. (PDF) A Study Protocol of an Open-Label Proof-of-Concept Trial, accessed February 17, 2026, [https://www.researchgate.net/publication/370159893\_A\_Study\_Protocol\_of\_an\_Open-Label\_Proof-of-Concept\_Trial\_Examining\_the\_Safety\_and\_Clinical\_Efficacy\_of\_Psilocybin-assisted\_Therapy\_for\_Veterans\_with\_PTSD](https://www.researchgate.net/publication/370159893_A_Study_Protocol_of_an_Open-Label_Proof-of-Concept_Trial_Examining_the_Safety_and_Clinical_Efficacy_of_Psilocybin-assisted_Therapy_for_Veterans_with_PTSD)  
24. A Phase I trial to inform clinical protocols for the safe administration, accessed February 17, 2026, [https://www.medrxiv.org/content/10.1101/2023.04.12.23288325v1.full-text](https://www.medrxiv.org/content/10.1101/2023.04.12.23288325v1.full-text)  
25. NCT06355414 | Psilocybin in Chronic Low Back Pain and Depression, accessed February 17, 2026, [https://clinicaltrials.gov/study/NCT06355414](https://clinicaltrials.gov/study/NCT06355414)  
26. Oregon Psilocybin Services Guidance on Administrative Rules, accessed February 17, 2026, [https://content.govdelivery.com/attachments/ORDHS/2024/01/02/file\_attachments/2733170/OPS-Guidance-on-Administrative-Rules.pdf](https://content.govdelivery.com/attachments/ORDHS/2024/01/02/file_attachments/2733170/OPS-Guidance-on-Administrative-Rules.pdf)  
27. Pilot Study of Psilocybin-Assisted Therapy for Demoralization in, accessed February 17, 2026, [https://clinicaltrials.gov/study/NCT04950608](https://clinicaltrials.gov/study/NCT04950608)  
28. Study Details | NCT02421263 | The Effects of Psilocybin-Facilitated, accessed February 17, 2026, [https://clinicaltrials.gov/study/NCT02421263](https://clinicaltrials.gov/study/NCT02421263)  
29. Psychedelic Assisted Therapy (PAT), accessed February 17, 2026, [https://ucebt.com/psychedelic-assisted-therapy/](https://ucebt.com/psychedelic-assisted-therapy/)  
30. A Dose-Ranging Study of 50 µg to 100 µg LSD in Healthy Volunteers, accessed February 17, 2026, [https://clinicaltrials.gov/study/NCT05674669](https://clinicaltrials.gov/study/NCT05674669)  
31. Acceptability & Safety of Two Sequential Doses of Psilocybin in, accessed February 17, 2026, [https://clinicaltrials.gov/study/NCT06706232?locStr=United%20States\&country=United%20States\&intr=Psilocybin\&limit=100\&rank=96](https://clinicaltrials.gov/study/NCT06706232?locStr=United+States&country=United+States&intr=Psilocybin&limit=100&rank=96)  
32. Psilocybin-assisted therapy for the treatment of resistant major, accessed February 17, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC8638462/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8638462/)  
33. Acceptability & Safety of Two Sequential Doses of Psilocybin in, accessed February 17, 2026, [https://trialfinder.panfoundation.org/en-US/trial/listing/557957](https://trialfinder.panfoundation.org/en-US/trial/listing/557957)  
34. Psilocybin-Assisted Randomized Therapy | ClinicalTrials.gov, accessed February 17, 2026, [https://clinicaltrials.gov/study/NCT07332143](https://clinicaltrials.gov/study/NCT07332143)  
35. Preliminary safety and effectiveness of psilocybin-assisted therapy, accessed February 17, 2026, [https://www.frontiersin.org/journals/pain-research/articles/10.3389/fpain.2025.1527783/full](https://www.frontiersin.org/journals/pain-research/articles/10.3389/fpain.2025.1527783/full)  
36. Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid, accessed February 17, 2026, [https://www.dana-farber.org/clinical-trials/23-325](https://www.dana-farber.org/clinical-trials/23-325)  
37. Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin, accessed February 17, 2026, [https://clinicaltrials.gov/study/NCT07169747](https://clinicaltrials.gov/study/NCT07169747)  
38. Study Details | NCT05847686 | Psilocybin-Assisted Therapy for the, accessed February 17, 2026, [https://clinicaltrials.gov/study/NCT05847686](https://clinicaltrials.gov/study/NCT05847686)  
39. Eligibility for psychedelic therapy: Clinical trial medical exclusion, accessed February 17, 2026, [https://www.researchgate.net/publication/398752663\_Eligibility\_for\_psychedelic\_therapy\_Clinical\_trial\_medical\_exclusion\_criteria\_and\_their\_implications\_for\_hospital\_practice](https://www.researchgate.net/publication/398752663_Eligibility_for_psychedelic_therapy_Clinical_trial_medical_exclusion_criteria_and_their_implications_for_hospital_practice)  
40. Moderating factors in psilocybin-assisted treatment affecting mood ..., accessed February 17, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11890248/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11890248/)  
41. Psychedelic-assisted grief therapy: a mixed-method case study, accessed February 17, 2026, [https://www.tandfonline.com/doi/pdf/10.1080/13576275.2024.2434456](https://www.tandfonline.com/doi/pdf/10.1080/13576275.2024.2434456)  
42. Psilocybin-Assisted Group Psychotherapy \+ Mindfulness Based, accessed February 17, 2026, [https://www.medrxiv.org/content/10.1101/2024.12.31.24319806v1.full-text](https://www.medrxiv.org/content/10.1101/2024.12.31.24319806v1.full-text)  
43. Protocol and Synopsis MAPPUSX IND \#063384 \- ClinicalTrials.gov, accessed February 17, 2026, [https://cdn.clinicaltrials.gov/large-docs/59/NCT04714359/Prot\_000.pdf](https://cdn.clinicaltrials.gov/large-docs/59/NCT04714359/Prot_000.pdf)  
44. Effects of MDMA-assisted therapy for PTSD on self-experience \- PMC, accessed February 17, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10781106/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10781106/)  
45. Are you Ready for a Psychedelic Experience? Take this quiz \- Althea, accessed February 17, 2026, [https://withalthea.com/2025/02/13/psychedelic-preparedness-scale/](https://withalthea.com/2025/02/13/psychedelic-preparedness-scale/)  
46. Yale Manual for Psilocybin-Assisted Therapy of Depression, accessed February 17, 2026, [http://uczesieact.pl/wp-content/uploads/2020/01/Yale-Psilocybin-Depression-Therapy-Manual\_Oct-2019.pdf](http://uczesieact.pl/wp-content/uploads/2020/01/Yale-Psilocybin-Depression-Therapy-Manual_Oct-2019.pdf)  
47. The therapeutic alliance between study participants and intervention, accessed February 17, 2026, [https://www.researchgate.net/publication/378973634\_The\_therapeutic\_alliance\_between\_study\_participants\_and\_intervention\_facilitators\_is\_associated\_with\_acute\_effects\_and\_clinical\_outcomes\_in\_a\_psilocybin-assisted\_therapy\_trial\_for\_major\_depressive\_dis](https://www.researchgate.net/publication/378973634_The_therapeutic_alliance_between_study_participants_and_intervention_facilitators_is_associated_with_acute_effects_and_clinical_outcomes_in_a_psilocybin-assisted_therapy_trial_for_major_depressive_dis)  
48. Preparation Guide \- Intero Psychedelic Therapy, accessed February 17, 2026, [https://www.intero-psychedelic.com/psychological-preparation-guide](https://www.intero-psychedelic.com/psychological-preparation-guide)  
49. Fundamentals of Psychedelic-Assisted Therapy \- Numinus, accessed February 17, 2026, [https://numinusnetwork.com/courses/fundamentals-of-psychedelic-assisted-therapy/](https://numinusnetwork.com/courses/fundamentals-of-psychedelic-assisted-therapy/)  
50. Oregon Administrative Rules, Division 333, Section 333-333-5040, accessed February 17, 2026, [https://regulations.justia.com/states/oregon/chapter-333/division-333/section-333-333-5040/](https://regulations.justia.com/states/oregon/chapter-333/division-333/section-333-333-5040/)  
51. Yale Manual for Psilocybin-Assisted Therapy : Advice for 'Difficult, accessed February 17, 2026, [https://www.reddit.com/r/RationalPsychonaut/comments/jvu4xf/yale\_manual\_for\_psilocybinassisted\_therapy\_advice/](https://www.reddit.com/r/RationalPsychonaut/comments/jvu4xf/yale_manual_for_psilocybinassisted_therapy_advice/)  
52. An Expert-Informed Introduction to the Elements of Psychedelic, accessed February 17, 2026, [https://www.brainfutures.org/wp-content/uploads/2022/10/An-Expert-Informed-Introduction-to-the-Elements-of-PAT\_web.pdf](https://www.brainfutures.org/wp-content/uploads/2022/10/An-Expert-Informed-Introduction-to-the-Elements-of-PAT_web.pdf)  
53. (PDF) The Yale Manual for Psilocybin-Assisted Therapy of, accessed February 17, 2026, [https://www.researchgate.net/publication/343645122\_The\_Yale\_Manual\_for\_Psilocybin-Assisted\_Therapy\_of\_Depression\_using\_Acceptance\_and\_Commitment\_Therapy\_as\_a\_Therapeutic\_Frame](https://www.researchgate.net/publication/343645122_The_Yale_Manual_for_Psilocybin-Assisted_Therapy_of_Depression_using_Acceptance_and_Commitment_Therapy_as_a_Therapeutic_Frame)  
54. (PDF) Music programming for psilocybin-assisted therapy: Guided, accessed February 17, 2026, [https://www.researchgate.net/publication/365484588\_Music\_programming\_for\_psilocybin-assisted\_therapy\_Guided\_Imagery\_and\_Music-informed\_perspectives](https://www.researchgate.net/publication/365484588_Music_programming_for_psilocybin-assisted_therapy_Guided_Imagery_and_Music-informed_perspectives)  
55. How Psilocybin Retreats Transform Mental Health Approaches, accessed February 17, 2026, [https://www.mycomeditations.com/blog/psychedelic-information/how-psilocybin-retreats-transform-mental-health-approaches/](https://www.mycomeditations.com/blog/psychedelic-information/how-psilocybin-retreats-transform-mental-health-approaches/)  
56. Oregon Psilocybin Services, accessed February 17, 2026, [https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Documents/OPS-Fact-Sheet.pdf](https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Documents/OPS-Fact-Sheet.pdf)  
57. Health and Safety \- Oregon Psilocybin Services, accessed February 17, 2026, [https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Documents/OPS-Health-and-Safety.pdf](https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Documents/OPS-Health-and-Safety.pdf)  
58. Client Safety and Support Plan | Oregon.gov, accessed February 17, 2026, [https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Documents/Client-Safety-and-Support-Plan.pdf](https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Documents/Client-Safety-and-Support-Plan.pdf)  
59. HAF: Oregon Psilocybin Services Client Guide, accessed February 17, 2026, [https://cdn.prod.website-files.com/6564e6039adc71a06c8e1530/672004e8e620ed486b264b48\_HAF\_%20Oregon%20Psilocybin%20Services%20Client%20Guide.pdf](https://cdn.prod.website-files.com/6564e6039adc71a06c8e1530/672004e8e620ed486b264b48_HAF_%20Oregon%20Psilocybin%20Services%20Client%20Guide.pdf)  
60. GAO-24-106630, DRUG CONTROL: DEA Should Improve its, accessed February 17, 2026, [https://www.gao.gov/assets/gao-24-106630.pdf](https://www.gao.gov/assets/gao-24-106630.pdf)  
61. Or. Admin. Code § 333-333-5000 \- \[Effective 1/1/2025\] Preparation, accessed February 17, 2026, [https://www.law.cornell.edu/regulations/oregon/Or-Admin-Code-SS-333-333-5000\_v2](https://www.law.cornell.edu/regulations/oregon/Or-Admin-Code-SS-333-333-5000_v2)  
62. Supportive Touch in Psychedelic Assisted Therapy | Request PDF, accessed February 17, 2026, [https://www.researchgate.net/publication/387977084\_Supportive\_Touch\_in\_Psychedelic\_Assisted\_Therapy](https://www.researchgate.net/publication/387977084_Supportive_Touch_in_Psychedelic_Assisted_Therapy)  
63. Oregon Health Authority, accessed February 17, 2026, [https://secure.sos.state.or.us/oard/view.action?ruleNumber=333-333-5120](https://secure.sos.state.or.us/oard/view.action?ruleNumber=333-333-5120)  
64. The ethical use of therapeutic touch in psychedelic-assisted therapy, accessed February 17, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC12618852/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12618852/)  
65. Can psychedelics enhance group psychotherapy? A discussion on, accessed February 17, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10350738/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10350738/)  
66. Set, Setting, and Safety: The Critical Foundation of Psychedelic, accessed February 17, 2026, [https://serenityprofessionalcounseling.com/set-setting-and-safety-the-critical-foundation-of-psychedelic-therapy](https://serenityprofessionalcounseling.com/set-setting-and-safety-the-critical-foundation-of-psychedelic-therapy)  
67. Explanatory Document \- The ReSPCT Guidelines, accessed February 17, 2026, [https://respctguidelines.com/the-explanatory-document/](https://respctguidelines.com/the-explanatory-document/)  
68. A Manual for MDMA-Assisted Psychotherapy in the Treatment of, accessed February 17, 2026, [https://maps.org/wp-content/uploads/2022/05/MDMA-Assisted-Psychotherapy-Treatment-Manual-V8.1-22AUG2017.pdf](https://maps.org/wp-content/uploads/2022/05/MDMA-Assisted-Psychotherapy-Treatment-Manual-V8.1-22AUG2017.pdf)  
69. The Multimodal Enrichment of the Psychoanalytic Space, accessed February 17, 2026, [https://opus.lib.uts.edu.au/bitstream/10453/171253/2/02whole.pdf](https://opus.lib.uts.edu.au/bitstream/10453/171253/2/02whole.pdf)  
70. Psychedelic Integration — FlowState Therapy, accessed February 17, 2026, [https://www.flowstatetherapy.ca/psychedelicintegration](https://www.flowstatetherapy.ca/psychedelicintegration)  
71. Johns Hopkins Center for Psychedelic and Consciousness Research, accessed February 17, 2026, [https://www.hopkinsmedicine.org/psychiatry/research/psychedelics-research](https://www.hopkinsmedicine.org/psychiatry/research/psychedelics-research)  
72. How to Prepare for Psychedelic Therapy: Set & Setting, accessed February 17, 2026, [https://www.seasonsofgrowthcounseling.com/blog/how-to-prepare-for-psychedelic-therapy-set-and-setting](https://www.seasonsofgrowthcounseling.com/blog/how-to-prepare-for-psychedelic-therapy-set-and-setting)  
73. actrn12623000832673 \- ANZCTR \- Registration, accessed February 17, 2026, [https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=385656\&isReview=true](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=385656&isReview=true)  
74. actrn12623001004651 \- ANZCTR \- Registration, accessed February 17, 2026, [https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=385585\&isReview=true](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=385585&isReview=true)  
75. Improving access to psilocybin-assisted therapy: barriers ... \- PMC, accessed February 17, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC12894259/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12894259/)  
76. Therapeutic use of psilocybin: Practical considerations for dosing, accessed February 17, 2026, [https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2022.1040217/full](https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2022.1040217/full)  
77. MAPS MDMA-Assisted Psychotherapy for PTSD | Sunstone Therapies, accessed February 17, 2026, [https://www.sunstonetherapies.com/science/clinical-trials/mdma-assisted-psychotherapy-for-post-traumatic-stress-disorder-maps-2021/](https://www.sunstonetherapies.com/science/clinical-trials/mdma-assisted-psychotherapy-for-post-traumatic-stress-disorder-maps-2021/)  
78. Music Therapy Improvisation in the Integration of Psychedelic, accessed February 17, 2026, [https://researchdiscovery.drexel.edu/view/pdfCoverPage?instCode=01DRXU\_INST\&filePid=13438781370004721\&download=true](https://researchdiscovery.drexel.edu/view/pdfCoverPage?instCode=01DRXU_INST&filePid=13438781370004721&download=true)  
79. What to Expect From Psilocybin Therapy: A Patient's Guide, accessed February 17, 2026, [https://renewhealth.com/what-to-expect-from-psilocybin-therapy-a-patients-guide/](https://renewhealth.com/what-to-expect-from-psilocybin-therapy-a-patients-guide/)  
80. A Protocol for Psilocybin Assisted Self-Development \- Webflow, accessed February 17, 2026, [https://uploads-ssl.webflow.com/5f7390dfac8708fbb8e78a8c/5fb9cd79ec09452ffd8ec945\_Blossom%20-%20Protocol%20v0.3.pdf](https://uploads-ssl.webflow.com/5f7390dfac8708fbb8e78a8c/5fb9cd79ec09452ffd8ec945_Blossom%20-%20Protocol%20v0.3.pdf)  
81. Interview with a Psychedelic Facilitator, accessed February 17, 2026, [https://psychedelics.ucsf.edu/blog/interview-with-a-psychedelic-facilitator](https://psychedelics.ucsf.edu/blog/interview-with-a-psychedelic-facilitator)  
82. Psychedelic Psychiatry \- The Center for Body Up Co-Regulation, accessed February 17, 2026, [https://wecoregulate.com/wp-content/uploads/2023/07/Journal-of-Psychedelic-Psychiatry.pdf](https://wecoregulate.com/wp-content/uploads/2023/07/Journal-of-Psychedelic-Psychiatry.pdf)  
83. A Manual for MDMA-Assisted Psychotherapy in the Treatment of, accessed February 17, 2026, [https://maps.org/research-archive/mdma/MDMA-Assisted-Psychotherapy-Treatment-Manual-Version7-19Aug15-FINAL.pdf](https://maps.org/research-archive/mdma/MDMA-Assisted-Psychotherapy-Treatment-Manual-Version7-19Aug15-FINAL.pdf)  
84. Finding the Silver Lining: How Tough Psychedelic Trips Can Lead to, accessed February 17, 2026, [https://serenityprofessionalcounseling.com/finding-the-silver-lining-how-tough-psychedelic-trips-can-lead-to-growth](https://serenityprofessionalcounseling.com/finding-the-silver-lining-how-tough-psychedelic-trips-can-lead-to-growth)  
85. The Psychedelic Explorer's Guide PDF \- Bookey, accessed February 17, 2026, [https://cdn.bookey.app/files/pdf/book/en/the-psychedelic-explorer's-guide.pdf](https://cdn.bookey.app/files/pdf/book/en/the-psychedelic-explorer's-guide.pdf)  
86. Extended difficulties following the use of psychedelic drugs: A mixed, accessed February 17, 2026, [https://www.researchgate.net/publication/374964098\_Extended\_difficulties\_following\_the\_use\_of\_psychedelic\_drugs\_A\_mixed\_methods\_study](https://www.researchgate.net/publication/374964098_Extended_difficulties_following_the_use_of_psychedelic_drugs_A_mixed_methods_study)  
87. Human hallucinogen research: guidelines for safety, accessed February 17, 2026, [https://files.csp.org/Psilocybin/HopkinsHallucinogenSafety2008.pdf](https://files.csp.org/Psilocybin/HopkinsHallucinogenSafety2008.pdf)  
88. Psychosis and psychedelics: Historical entanglements ... \- PMC \- NIH, accessed February 17, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9660273/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9660273/)  
89. Psychedelic Treatment with Psilocybin: Addressing Medical, accessed February 17, 2026, [https://www.cambridge.org/core/journals/journal-of-law-medicine-and-ethics/article/psychedelic-treatment-with-psilocybin-addressing-medical-malpractice-risk-and-physicians-concerns/6704BF55918591072802E2304C94DAB1?trk=feed\_main-feed-card\_reshare\_feed-article-content](https://www.cambridge.org/core/journals/journal-of-law-medicine-and-ethics/article/psychedelic-treatment-with-psilocybin-addressing-medical-malpractice-risk-and-physicians-concerns/6704BF55918591072802E2304C94DAB1?trk=feed_main-feed-card_reshare_feed-article-content)  
90. Therapists report significant psychological risks in psilocybin, accessed February 17, 2026, [https://www.reddit.com/r/science/comments/1cg4xka/therapists\_report\_significant\_psychological\_risks/](https://www.reddit.com/r/science/comments/1cg4xka/therapists_report_significant_psychological_risks/)  
91. Professional Practice Guidelines for Psychedelic-Assisted Therapy, accessed February 17, 2026, [https://www.brainfutures.org/wp-content/uploads/2023/08/Professional-Practice-Guidelines-for-Psychedelic-Assisted-Therapy-Aug-2023.pdf](https://www.brainfutures.org/wp-content/uploads/2023/08/Professional-Practice-Guidelines-for-Psychedelic-Assisted-Therapy-Aug-2023.pdf)  
92. Considerations and cautions for the integration of psilocybin into, accessed February 17, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC12495261/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12495261/)  
93. Psychedelic treatment and mental health: Navigating a longer trip, accessed February 17, 2026, [https://www.apa.org/monitor/2025/01/trends-psychedelic-treatments](https://www.apa.org/monitor/2025/01/trends-psychedelic-treatments)  
94. Ketamine Therapy Integration: How to Maximize Post‑Session Healing, accessed February 17, 2026, [https://modmeds.life/ketamine-therapy-integration-how-to-maximize-post%E2%80%91session-healing/](https://modmeds.life/ketamine-therapy-integration-how-to-maximize-post%E2%80%91session-healing/)  
95. Therapeutic frameworks in integration sessions in substance, accessed February 17, 2026, [https://researchportal.murdoch.edu.au/view/pdfCoverPage?instCode=61MUN\_INST\&filePid=13155517730007891\&download=true](https://researchportal.murdoch.edu.au/view/pdfCoverPage?instCode=61MUN_INST&filePid=13155517730007891&download=true)  
96. Study Details | NCT07072728 | Psilocybin-Assisted Psychotherapy, accessed February 17, 2026, [https://clinicaltrials.gov/study/NCT07072728](https://clinicaltrials.gov/study/NCT07072728)  
97. Methods and Approaches for Psychedelic Therapy Integration, accessed February 17, 2026, [https://pratigroup.org/psychedelic-therapy/methods-and-approaches-for-psychedelic-therapy-integration/](https://pratigroup.org/psychedelic-therapy/methods-and-approaches-for-psychedelic-therapy-integration/)  
98. The Beginners Guide to Psychedelic Integration: Key Steps, accessed February 17, 2026, [https://inwardbound.nl/psychedelic-integration/](https://inwardbound.nl/psychedelic-integration/)  
99. Ketamine Integration Circles in the Virginia Area \- Avesta, accessed February 17, 2026, [https://avestaketaminewellness.com/exploring-ketamine-integration-circles-in-virginia/](https://avestaketaminewellness.com/exploring-ketamine-integration-circles-in-virginia/)  
100. Measuring psychotherapeutic processes in the context of ... \- PMC, accessed February 17, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11102652/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11102652/)  
101. Psychedelic-assisted EMDR therapy (PsyA-EMDR): A memory, accessed February 17, 2026, [https://etq.emdrassociation.org.uk/2023/02/16/psychedelic-assisted-emdr-therapy-psya-emdr-a-memory-consolidation-approach-to-psychedelic-healing/](https://etq.emdrassociation.org.uk/2023/02/16/psychedelic-assisted-emdr-therapy-psya-emdr-a-memory-consolidation-approach-to-psychedelic-healing/)  
102. The Psychedelic Integration Scales: Tools for Measuring ... \- PMC, accessed February 17, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9168432/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9168432/)  
103. Measuring and Enhancing Psychedelic Preparedness, accessed February 17, 2026, [https://discovery.ucl.ac.uk/id/eprint/10212132/9/McAlpine\_10212132\_thesis.pdf](https://discovery.ucl.ac.uk/id/eprint/10212132/9/McAlpine_10212132_thesis.pdf)  
104. Evaluation of the peak experience scale as a rapid assessment tool, accessed February 17, 2026, [https://www.frontiersin.org/journals/psychology/articles/10.3389/fpsyg.2025.1543640/full](https://www.frontiersin.org/journals/psychology/articles/10.3389/fpsyg.2025.1543640/full)  
105. (PDF) The Psychedelic Integration Scales: Tools for Measuring, accessed February 17, 2026, [https://www.researchgate.net/publication/360786803\_The\_Psychedelic\_Integration\_Scales\_Tools\_for\_Measuring\_Psychedelic\_Integration\_Behaviors\_and\_Experiences](https://www.researchgate.net/publication/360786803_The_Psychedelic_Integration_Scales_Tools_for_Measuring_Psychedelic_Integration_Behaviors_and_Experiences)  
106. Study protocol of an open-label proof-of-concept trial examining the, accessed February 17, 2026, [https://bmjopen.bmj.com/content/13/5/e068884](https://bmjopen.bmj.com/content/13/5/e068884)  
107. EMDR as a preparation and integration tool in psychedelic-assisted, accessed February 17, 2026, [https://etq.emdrassociation.org.uk/case-study/emdr-as-a-preparation-and-integration-tool-in-psychedelic-assisted-therapy/](https://etq.emdrassociation.org.uk/case-study/emdr-as-a-preparation-and-integration-tool-in-psychedelic-assisted-therapy/)  
108. A memory consolidation approach to psychedelic healing, accessed February 17, 2026, [https://www.researchgate.net/publication/369570095\_Psychedelic\_assisted\_EMDR\_therapy\_PsyA-EMDR\_A\_memory\_consolidation\_approach\_to\_psychedelic\_healing](https://www.researchgate.net/publication/369570095_Psychedelic_assisted_EMDR_therapy_PsyA-EMDR_A_memory_consolidation_approach_to_psychedelic_healing)  
109. protocol for a randomized, waitlist-controlled trial with blinded ratings, accessed February 17, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10803438/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10803438/)  
110. A phase 1/2 trial to assess safety and efficacy of a vaporized 5, accessed February 17, 2026, [https://www.researchgate.net/publication/371737938\_A\_phase\_12\_trial\_to\_assess\_safety\_and\_efficacy\_of\_a\_vaporized\_5-methoxy-NN-dimethyltryptamine\_formulation\_GH001\_in\_patients\_with\_treatment-resistant\_depression](https://www.researchgate.net/publication/371737938_A_phase_12_trial_to_assess_safety_and_efficacy_of_a_vaporized_5-methoxy-NN-dimethyltryptamine_formulation_GH001_in_patients_with_treatment-resistant_depression)

# **Tab 2**

\# Provider-View Operations for Psychedelic Therapy Treatments 📈

\#\# Executive summary

Licensed clinics running ketamine and other regulated programs succeed or fail on operational discipline, not on marketing. The provider-side outcomes that matter in B2B terms are: predictable safety, defensible documentation, repeatable workflows, measurable outcomes, and reimbursement-ready records. The strongest public “gold standard” pattern is a sedation-adjacent medical workflow with (1) rigorous pre-treatment screening, (2) standardized monitoring and emergency readiness, (3) measurement-based care with defined stop and pause thresholds, and (4) structured follow-up and integration. citeturn13view0turn33view0turn30view0turn8view0turn5search4

For ketamine clinics, authoritative guidance converges on: treat only appropriately selected patients, monitor blood pressure, heart rate, oxygenation, and level of consciousness before, during, and after dosing, have Advanced Cardiac Life Support capability on-site, and document “time-out,” dose, route, infusion settings, adverse events, and discharge safety. citeturn13view0turn33view0turn30view0turn9view0turn9view1

For regulated psilocybin programs, the workflow is regulation-driven and documentation-heavy. In entity\["state","Oregon","us state"\], psilocybin services are explicitly not “medical treatment” in the program’s informed consent, the model is “non-directive,” and required client forms and operational rules govern intake, transportation planning, safety/support planning, product transfer, minimum session durations, facilitator ratios for group sessions, adverse reaction reporting, and release criteria. citeturn18view0turn35search6turn14view0turn19view0turn19view1turn35search1turn35search9turn21view0turn20view0

For entheogenic religion operators seeking legitimacy and legal protection, the business transformation is from “informal ceremony” to “auditable compliance system.” The public record shows that federal religious exemptions under the Religious Freedom Restoration Act are procedurally complex, and stakeholders report barriers and uncertainty. You should expect high legal overhead, strict governance needs, and a long runway to stable legitimacy. citeturn2search5turn2search6turn2search8

\#\# Regulatory and business models that shape workflow

A licensed ketamine clinic operates in a medical model with a federally scheduled controlled substance. Ketamine is identified by the entity\["organization","Drug Enforcement Administration","drug law enforcement, us"\] and DEA Diversion materials as a Schedule III controlled substance, which drives secure storage, prescribing controls, and diversion risk management. citeturn27search0turn27search4turn27search7

A “regulated psilocybin services” operator is typically not running a medical practice model, even if medical professionals participate in parts of the workflow. In Oregon’s program, informed consent explicitly states services are not medical or clinical treatment, while acknowledging federal Schedule I status. citeturn18view0turn15view1

A key practitioner-facing change in Oregon beginning in 2026 is “dual licensure,” allowing facilitators who also hold certain professional licenses to provide health care or behavioral health services during preparation and integration sessions, but not during the administration session. This creates a hybrid B2B model where the business can offer clinically oriented prep and integration while keeping administration non-directive and within the program’s scope. citeturn14view0turn22view0turn22view1turn21view3

In entity\["state","Colorado","us state"\], the natural medicine framework is also governance-driven, with healing centers required to maintain administration session logs, adverse-event reporting, and emergency plans, and with informed-consent and termination-process requirements spelled out in state regulations. citeturn26view1turn26view0turn23search2

Reimbursement reality is central to “practitioner pain.” Major payers frequently classify IV ketamine for depression as investigational or not established, which pushes clinics toward cash-pay or complex out-of-network strategies. entity\["company","Aetna","us health insurer"\], for example, states ketamine-assisted therapy is experimental/investigational/unproven for depression in its clinical policy bulletin. citeturn12search0 A entity\["company","Blue Cross Blue Shield of Massachusetts","us health insurer, ma"\] policy similarly labels IV ketamine for mental health as investigational in many situations. citeturn12search1 In contrast, esketamine has an FDA-approved labeling and a REMS that creates a clearer operational standard, which is why it is often more reimbursable, even though it imposes monitoring and documentation burdens. citeturn5search0turn5search4turn12search2

\#\# Phase-based clinical operations and controls

This section is written as an operational “provider playbook,” with differences called out for ketamine clinics versus regulated psilocybin services.

\`\`\`mermaid  
flowchart TD  
  A\[Inbound inquiry\] \--\> B\[Intake triage and education\]  
  B \--\> C\[Clinical evaluation and eligibility\]  
  C \--\> D\[Consent \+ legal/financial disclosure\]  
  D \--\> E\[Preparation planning\]  
  E \--\> F\[Treatment session\]  
  F \--\> G\[Recovery \+ discharge clearance\]  
  G \--\> H\[Follow-up \+ integration\]  
  H \--\> I\[Outcome review \+ maintenance plan\]  
  I \--\>|If response sustained| J\[Spacing / discontinuation\]  
  I \--\>|If partial response| E  
  I \--\>|If adverse events or no benefit| K\[Stop, refer, alternative care\]  
\`\`\`  
This flow reflects the standard operating procedure emphasis in ketamine consensus guidance, sedation guidelines, and regulated program rules that require preparation, administration, and integration sessions, plus discharge and follow-up. citeturn13view0turn33view0turn8view0turn35search6turn21view0

\#\#\# First contact, intake, and evaluation

Core B2B objective: convert an inquiry into a medically and legally defensible “go/no-go” decision while minimizing clinician time spent on ineligible patients.

Intake actions and workflow controls    
For ketamine clinics, a “pre-admission evaluation” approach is recommended so you can complete work-up days to weeks before treatment day, not in the chair. This includes treatment resistance verification, psychiatric assessment, medical comorbidity screening, and indicated testing. citeturn30view0turn33view0turn13view0 For regulated psilocybin services in Oregon, rules require a preparation session at least 24 hours and no more than 90 days before the first administration session, with required forms and written consents completed before administration. citeturn35search6turn18view0turn14view0

Personnel roles    
A typical ketamine clinic team in public guidance includes: a prescribing clinician with controlled-substance authority and ACLS capability, registered nurses monitoring during and after treatment, and access to psychiatric evaluation for behavioral risks prior to discharge. citeturn13view0turn31view0turn33view0 In regulated Oregon psilocybin services, the licensed facilitator is the primary contact across preparation, administration, and integration, and the facilitator role is defined as non-directive during administration. citeturn22view1turn18view0turn14view0

Screening tools and practical thresholds    
For ketamine, major public clinical recommendations include baseline vital sign assessment and defined blood pressure thresholds. CANMAT recommends not initiating infusion if baseline blood pressure is greater than 140/90 and pausing the infusion if blood pressure rises above 160/100, resuming when below that threshold, with or without antihypertensive treatment. citeturn33view0turn35search11 The entity\["organization","College of Physicians and Surgeons of British Columbia","medical regulator, british columbia"\] standard requires obstructive sleep apnea screening using a validated tool such as STOP-Bang during pre-admission assessment. citeturn31view4turn34search3

For regulated psilocybin services in Oregon, the Client Information Form creates bright-line exclusions and escalation triggers. “Yes” to lithium use in the last 30 days or current thoughts of harming self or others or history/diagnosis of active psychosis bars participation in an administration session. Other “yes” answers trigger consultation encouragement and planning requirements (medications, interpreter needs, mobility devices, support person plans). citeturn14view0

Recommended measurement-based intake for licensed clinics is to operationalize symptoms, function, and risk using validated tools. In publicly visible clinic routines described by patients, it is common to complete PHQ-9 and GAD-7 at each visit and attach physiologic monitoring before dosing. citeturn36search0turn34search0turn34search5 PHQ-9 score bands and cutpoints are widely published and support severity stratification. citeturn34search0turn34search20

Medical and psychiatric risk checks    
Ketamine guidance consistently elevates cardiovascular risk, psychosis/mania risk, substance use disorder, pregnancy/breastfeeding, and unstable medical conditions as key concerns. CANMAT lists relative contraindications including psychotic symptoms, poorly controlled hypertension, unstable medical conditions, substance use/dependence, and pregnancy/breastfeeding, and recommends ECG and urine toxicology when indicated. citeturn33view0turn30view0 The APA ketamine consensus statement highlights the need to manage cardiovascular and behavioral risks, and to ensure on-site evaluation for suicidal ideation before discharge. citeturn13view0turn27search0

Consent and legal documentation    
For ketamine, informed consent should be explicit about off-label use, risks, alternatives, and the likelihood of needing maintenance rather than cure. citeturn13view0turn7view0 The CPSBC standard even addresses “rolling consent” across repeated consecutive visits, requiring documentation that consent remains valid at each visit. citeturn30view0

For Oregon psilocybin services, required documents include an informed consent form, Client Bill of Rights, product potency information discussion, a transportation plan, and a safety and support plan, and there are rules about what must be reviewed in preparation. citeturn18view0turn15view0turn15view1turn35search6turn19view0turn19view1

Common operational pain points in this phase    
For ketamine clinics: the biggest friction is the gap between what good medicine requires and what payers reimburse. Professional guidance explicitly connects cost pressure and lack of coverage to the rise of less supervised at-home protocols, with associated misuse and diversion concerns. citeturn11view0turn12search0turn12search3 For psilocybin facilitators in Oregon: practitioners and clients frequently express frustration that the model is non-directive and not “therapy,” alongside concerns about high licensing fees and limited ability to integrate mental health treatment during administration. citeturn22view1turn36search11turn18view0

\#\#\# Treatment session

Core B2B objective: deliver a repeatable session that is safe, monitored, and documented to a standard you can defend in audits, claims, and complaints.

Physical setting and setup    
Ketamine clinics commonly use a private, low-stimulation room with a recliner or bed space, plus continuous physiologic monitoring. This aligns with published facility requirements that each treatment space be equipped with automatic blood pressure monitoring, pulse oximetry, suction, oxygen, bag-valve-mask device, and airway equipment, with cardiac monitoring available. citeturn31view0turn31view3turn9view1

Psychedelic session “set and setting” in classic hallucinogen research emphasizes a comfortable room, prolonged observation, and trained monitors. The entity\["organization","Johns Hopkins University","research university, maryland"\] safety guidelines recommend at least two monitors present during administration, reflecting the “never alone” standard used in research environments. citeturn3search1turn3search4

Personnel roles during session    
For ketamine, consensus statements emphasize that clinicians delivering treatment should be prepared to manage cardiovascular events, monitor physiologic and mental status, and respond to behavioral emergencies. citeturn13view0turn33view0turn7view0 The CPSBC standard specifies that registered nurses monitoring ketamine patients must be qualified and ACLS-trained. citeturn31view0

For Oregon psilocybin administration sessions, the facilitator is required to remain responsible for monitoring and support until safe release, and service center licensee representatives have defined operational roles. citeturn15view0turn21view0turn3search2

Monitoring equipment and protocols    
A robust ketamine clinic protocol borrows from moderate sedation safety design. The entity\["organization","American Society of Anesthesiologists","us anesthesia society"\] 2018 moderate procedural sedation guidelines emphasize monitoring ventilation and oxygenation using clinical observation plus pulse oximetry and capnography, hemodynamic monitoring including blood pressure and heart rate, contemporaneous recording, and the availability of someone capable of airway rescue, with suction and oxygen immediately available. citeturn9view0turn9view1turn9view2

Ketamine-specific guidance adds explicit post-infusion monitoring durations. CANMAT recommends monitoring blood pressure, heart rate, oximetry, and level of consciousness before and during infusions and for at least 1 hour post-infusion. citeturn33view0turn35search11 The CPSBC standard describes minimum monitoring documentation points (baseline, 5 minutes into infusion, mid-infusion, end-infusion, and 1 hour post-infusion) and minimum length of stay (60 minutes in the treatment area after infusion discontinuation). citeturn31view1turn31view3

Dosing rationale and administration steps    
For ketamine clinics, the most commonly cited depression protocol is a subanesthetic, weight-based dose delivered IV over 40 minutes. The APA consensus statement describes 0.5 mg/kg over 40 minutes as the typical dose used in mood disorder studies and highlights that this dose can raise blood pressure and heart rate. citeturn13view0 CANMAT similarly lists 0.5 mg/kg over 40 minutes as the typical protocol, often repeated 2 to 3 times per week for 4 to 8 infusions. citeturn33view0 The CPSBC standard requires infusion control devices with locked control panels, a dedicated line, continuous infusion only (no bolus), and an independent double-check of infusion settings. citeturn30view0turn31view1

For IM and oral/sublingual ketamine, the evidence base is weaker and operational risk increases because onset and bioavailability are more variable. CANMAT rates oral ketamine evidence as limited and recommends that non-IV formulations be used only by specialists with ketamine-prescribing expertise, while warning about misuse and diversion. citeturn33view0turn11view0

For regulated Oregon psilocybin services, the workflow is explicitly documented: products are tested, packaged, and labeled before transfer to a service center, and the client’s consumption is observed, with maximum dose and minimum session durations defined in rules and program documents. citeturn15view1turn35search1turn3search2 The operational product and end-of-session form requires documentation of product type, dosage, quantity, unique identifier, and whether primary and secondary doses were consumed, and requires a signed release at the end of session with explicit release criteria. citeturn21view3turn21view0

Safety, emergency procedures, and harm reduction    
Ketamine: stop and pause triggers should be pre-written, not improvised. CANMAT provides specific blood pressure do-not-start and pause thresholds. citeturn33view0 Facilities should have emergency equipment and medications available consistent with sedation-risk profiles, including oxygen delivery, suction, airway tools, and emergency medications. citeturn9view1turn31view3

Oregon psilocybin: service centers must have safety and emergency plans including evacuation and emergency response procedures, and facilitators and staff must contact emergency medical services when there is an immediate or potential life threat, then notify the authority within required timeframes. citeturn4search0turn3search3turn3search7turn20view0 Additionally, clients are prohibited from driving after sessions and must follow pre-arranged transportation plans, with escalation to emergency services if safety issues cannot be resolved. citeturn19view0turn15view1turn18view0

Data capture during session    
For ketamine, measurement-based care recommendations explicitly include outcome rating scales plus monitoring dissociative symptoms using validated tools such as the Clinician-Administered Dissociative States Scale (CADSS) and modified Brief Psychiatric Rating Scale (BPRS), with monitoring at baseline, midpoint, endpoint, and 1 hour post-infusion. citeturn33view0turn35search11 For esketamine, REMS materials require monitoring for at least 2 hours for sedation, dissociation, and respiratory depression using pulse oximetry and vital signs, reinforced in prescribing information. citeturn5search4turn5search0turn5search12

Billing and reimbursement touchpoints during treatment    
A practical B2B rule is that reimbursement follows documentation, and documentation follows standardization. Esketamine has more defined billing pathways, including Medicare billing and coding guidance, because it is FDA-approved and tied to REMS program operational requirements. citeturn12search2turn5search4turn5search0

For IV ketamine, reimbursement is inconsistent and frequently denied as investigational in payer policies, which is why some organizations have issued position statements advocating for coverage. citeturn12search0turn12search1turn12search3 Some Medicaid programs publish detailed billing instructions for IV ketamine infusion therapy, including drug code usage and infusion administration code timing rules, illustrating how sensitive payment can be to coding mechanics. citeturn12search10

\#\#\# Post-treatment and integration

Core B2B objective: translate an acute drug session into durable outcomes and reduce downstream risk, including relapse, adverse events, complaints, and poor reviews.

Immediate recovery and discharge clearance    
For ketamine, discharge should not rely on a patient saying they feel fine. CANMAT recommends discharge only after physiologic measures and mental state return to baseline. citeturn33view0 The CPSBC standard requires physician assessment just prior to discharge to evaluate behavioral risks including suicidal ideation, and advises patients not to drive or operate hazardous machinery for at least 24 hours after ketamine administration. citeturn31view1

For Oregon psilocybin, release requires that minimum session duration is met based on total psilocybin analyte consumed, that both client and facilitator are comfortable ending the session, and that the client agrees to follow the transportation plan. citeturn21view0turn19view0

Integration sessions and follow-up cadence    
For ketamine, there is no single mandated integration model, but multiple authorities encourage psychotherapy when possible, particularly for trauma and anxiety presentations, and emphasize rapid follow-up availability when psychiatric symptoms worsen. citeturn13view0turn7view0turn33view0 In provider and patient discourse, “integration” language is very common and often framed as using the post-session “plasticity window” for behavioral change, journaling, mindfulness, and processing. citeturn36search6turn36search2

For Oregon psilocybin services, the program operational form requires that facilitators attempt to contact clients within 72 hours of the conclusion of an administration session to offer integration information and other services, and adverse reactions within 72 hours post-release are explicitly tracked as “post-session reactions.” citeturn21view0turn20view0

Quality assurance and incident learning    
Sedation-adjacent standards emphasize quality improvement processes, not just clinical technique. The ASA sedation guidelines call out creation and implementation of quality improvement processes for moderate sedation. citeturn8view0turn9view0 The CPSBC standard requires quality improvement strategies and a quality performance program to monitor, evaluate, and improve services. citeturn30view0turn31view1 For Oregon psilocybin services, rule-based forms, record retention, and reporting structures create auditability, and the informed consent includes explicit misconduct reporting duties. citeturn18view0turn20view0turn22view1

\#\#\# Repeat cycles and discontinuation

Ketamine repeat cycles    
Evidence summaries acknowledge rapid but often transient effects after single IV ketamine infusions, with relapse common within about 10 days for many patients, which is why repeated induction series and maintenance spacing are widely practiced, though longer-term efficacy evidence is still limited. citeturn33view0turn13view0 Standardized induction patterns in public guidance include 4 to 8 infusions, 2 to 3 times per week, with maintenance determined case by case. citeturn33view0turn30view0turn7view0

Psilocybin repeat cycles in regulated programs    
Oregon’s informed consent explicitly states that risks and benefits of repeated psilocybin use are unknown, and the program documents caution that risks and benefits above certain dose thresholds are unknown. citeturn18view0turn15view1 Operationally, Oregon rules allow “secondary doses” within an administration session, capped by a maximum total analyte amount, with storage, consent requirements, and documentation of unused product. citeturn21view3turn3search2

Discontinuation criteria    
Across models, the defendable stop rules are: lack of benefit after a pre-defined trial, intolerable adverse events, emerging mania/psychosis or unsafe behaviors, inability to comply with transportation or safety planning, and payer or legal noncompliance. This matches both ketamine safety guidance emphasizing behavioral risk monitoring and regulated program rules that hard-stop participation with certain risk markers. citeturn13view0turn33view0turn14view0turn18view0

\#\# Protocol comparison tables

The tables below compare operationally relevant features, not just pharmacology. Where public sources do not provide a single universal rule, the table reflects consensus patterns and regulatory requirements.

\#\#\# Ketamine route comparison for licensed clinics

| Dimension | IV ketamine in clinic | IM ketamine in clinic | Oral/Sublingual ketamine (clinic or hybrid) |  
|---|---|---|---|  
| Evidence strength for depression workflows | Strongest evidence base in consensus guidance and common research protocols. citeturn13view0turn33view0 | Limited evidence base relative to IV, with mixed study designs. citeturn13view0turn10search2turn10search6 | Limited evidence, higher variability, and higher misuse/diversion concern. citeturn33view0turn11view0turn10search3 |  
| Administration control | Highest precision via infusion pump, with double-check and locked controls recommended in formal standards. citeturn30view0 | Less precise than IV; still requires medical supervision and monitoring given physiologic effects. citeturn35search3turn13view0 | Lowest precision due to variability in bioavailability and onset, making clinic-level standardization harder. citeturn11view0turn33view0 |  
| Minimum monitoring pattern | Monitor vitals, oximetry, and consciousness before/during/at least 1 hour post; capnography recommended depending on sedation risk. citeturn33view0turn31view3turn9view0 | Similar monitoring expectations to IV in responsible practice due to BP and dissociation risk. citeturn13view0turn35search3 | Monitoring varies widely; professional concerns emphasize at-home risk and need for support person, safe environment, controlled prescribing. citeturn11view0turn33view0 |  
| Common BP safety thresholds in public guidance | Do-not-start \>140/90; pause/stop if \>160/100 per CANMAT. citeturn33view0turn35search11 | No universal IM-specific threshold published broadly; clinics typically adapt IV thresholds. citeturn33view0turn35search3 | Same physiologic concerns exist; risk increases with patient noncompliance and variable absorption. citeturn11view0turn33view0 |  
| Documentation “must-haves” | Dose, weight, route, infusion time, pump settings, vitals timeline, adverse events, discharge readiness, follow-up plan. citeturn13view0turn30view0turn33view0 | Dose, route, timing, vitals, adverse events, discharge safety, follow-up. citeturn13view0turn10search2 | Dose supplied, counseling, storage/diversion steps, follow-up intervals, adverse event escalation rules. citeturn11view0turn33view0 |  
| Reimbursement posture | Frequently denied as investigational for depression by major payers, driving cash-pay reliance. citeturn12search0turn12search1 | Similar reimbursement issues to IV. citeturn12search0turn12search1 | Often positioned as compounded/off-label, increasing payer and regulator scrutiny. citeturn11view0turn12search0 |

\#\#\# Psilocybin delivery model comparison

| Dimension | Ceremonial or entheogenic model | Regulated psilocybin program model |  
|---|---|---|  
| Legal posture in the U.S. | Federal Schedule I, with some groups seeking Religious Freedom Restoration Act accommodations; process is complex and uncertain. citeturn2search5turn2search8turn27search1 | State-regulated models exist, but federal Schedule I status remains, creating cross-jurisdiction complexity. citeturn15view1turn18view0 |  
| Provider role definition | Often framed as “facilitator/guide” with set-and-setting emphasis; best public safety guidance comes from human hallucinogen research safeguards. citeturn3search1turn3search4 | In Oregon, facilitator is non-directive during administration, with defined required prep and integration sessions and required forms. citeturn22view1turn35search6turn18view0 |  
| Intake exclusions and triggers | Varies by operator; best-practice screening is not universally standardized in public sources. citeturn3search4turn2search5 | Oregon Client Information Form includes bright-line exclusions (recent lithium, active self-harm intent, active psychosis) and explicit planning triggers. citeturn14view0 |  
| Session duration and release rules | Varies widely. citeturn3search4 | Oregon rules define minimum administration durations by analyte dose bands and require defined release criteria plus transportation plan compliance. citeturn35search1turn21view0turn19view0 |  
| Adverse event governance | Often inconsistent, which becomes a legitimacy and liability exposure if seeking legal protection. citeturn2search5turn3search4 | Oregon has defined adverse reaction documentation categories, includes post-session reactions within 72 hours, and has reporting duties. citeturn20view0turn3search7turn18view0 |  
| Data and privacy | Varies widely, often informal. citeturn2search5turn3search4 | Oregon includes client rights, confidentiality rules, and opt-out constructs for de-identified data; client-facing forms reflect these. citeturn15view0turn18view0 |

\#\# Measurement and documentation toolkit

This section provides templates you can adapt. Where a regulated program mandates a specific form, use the mandated version and treat the templates below as internal checklists.

\#\#\# Sample measurement schedules

Ketamine clinic measurement schedule aligned to published guidance    
The scheduling below aligns with CANMAT’s recommended monitoring timepoints and measurement-based care approach, plus common validated tools used in practice. citeturn33view0turn34search0turn34search5turn34search10

| Timepoint | Physiologic monitoring | Patient-reported outcomes | Clinician-rated safety checks |  
|---|---|---|---|  
| Screening visit (days to weeks prior) | Baseline vitals; consider ECG and labs when indicated; OSA screen via STOP-Bang. citeturn33view0turn31view4turn30view0 | PHQ-9, GAD-7 baseline; functional baseline. citeturn34search0turn34search5 | Suicidality assessment tool such as C-SSRS if risk present; substance use assessment. citeturn34search10turn33view0 |  
| Treatment day, pre-dose | Blood pressure, heart rate, oximetry, level of consciousness. citeturn33view0 | PHQ-9 and GAD-7 if doing session-by-session tracking. citeturn36search0turn34search0 | Clearance checklist: no new contraindications, no intoxication, ride confirmed, consent confirmed. citeturn13view0turn30view0 |  
| During infusion | Monitor BP, HR, oximetry, consciousness; consider capnography if sedation risk. citeturn33view0turn9view0turn31view3 | Brief tolerability prompts (nausea, anxiety). citeturn33view0turn35search11 | Dissociation/psychotomimetic symptoms via validated scale when feasible. citeturn33view0turn35search11 |  
| 1 hour post-infusion minimum | Continued vitals monitoring and discharge readiness assessment. citeturn33view0turn31view3 | Quick global improvement rating; plan for next session. citeturn33view0turn7view0 | Screen for suicidal ideation and severe behavioral effects prior to discharge. citeturn13view0turn31view1 |  
| 24 to 72 hours after | Telehealth or async check-in for adverse effects and symptom change. citeturn13view0turn11view0 | Repeat PHQ-9 and targeted goal tracking. citeturn34search0 | Escalate if worsening mood, suicidality, mania, or substance misuse signals. citeturn13view0turn33view0 |  
| End of induction series | Review outcomes and decide maintenance spacing or discontinuation. citeturn33view0turn7view0 | Trend PHQ-9 and function; define response and remission. citeturn34search0turn33view0 | Document rationale for maintenance or stopping. citeturn33view0turn13view0 |

Oregon regulated psilocybin services measurement schedule aligned to required operational steps    
Oregon’s program is defined around preparation, administration, integration sessions, plus post-session reaction tracking. citeturn18view0turn35search6turn21view0turn20view0

\- Preparation session: complete and sign Client Information Form, transportation plan, safety and support plan, and review informed consent and Client Bill of Rights. citeturn35search6turn14view0turn19view0turn19view1turn18view0turn15view0    
\- Administration session: document product transfer and end-of-session release criteria, including minimum duration rules and transportation compliance. citeturn21view3turn35search1turn21view0turn19view0    
\- 72-hour window: attempt post-session contact for integration info and track post-session reactions that involve emergency services or medical care. citeturn21view0turn20view0

\#\#\# Suggested documentation templates and checklists

Ketamine clinic intake checklist template    
This template reflects consensus guidance priorities: TRD verification, medical risk screening, informed consent, and safety planning. citeturn33view0turn13view0turn30view0

\- Referral story: diagnosis, duration, prior treatments, TRD criteria met, current meds. citeturn33view0turn30view0    
\- Contraindication screen: psychosis history, mania history, uncontrolled hypertension, unstable cardiac/respiratory disease, pregnancy/breastfeeding, substance use disorder. citeturn33view0turn11view0    
\- Baseline testing when indicated: ECG, urine toxicology, renal and liver function; OSA screening (STOP-Bang). citeturn33view0turn31view4turn30view0    
\- Consent packet: off-label disclosure, benefits/limits, risks (BP, dissociation), alternatives, maintenance likelihood, no-driving rule, transport requirement. citeturn13view0turn7view0turn31view1    
\- Operational plan: induction schedule, monitoring plan, emergency readiness, integration plan, outcomes tracking plan. citeturn33view0turn8view0

Ketamine infusion day “time-out” template    
The APA consensus statement recommends site-specific standard operating procedures including baseline vitals, confirmation of correct dosing parameters, and stopping criteria. citeturn13view0turn30view0

\- Patient identity confirmed, indication confirmed, consent confirmed as current. citeturn30view0turn13view0    
\- Baseline vitals documented and within your policy thresholds. citeturn33view0turn13view0    
\- Dose calculation verified, pump settings verified, independent double-check completed. citeturn30view0    
\- Monitoring devices on, alarms set, emergency equipment ready, rescue plan known to staff. citeturn9view1turn31view3turn8view0    
\- Stop criteria reviewed: BP thresholds, airway compromise, severe agitation, dissociation outside expectations. citeturn33view0turn13view0    
\- Transport confirmed: no driving for at least 24 hours per conservative standards. citeturn31view1turn13view0

Oregon psilocybin services internal compliance checklist    
This is not a substitute for program forms, it is a “do not miss” audit list built from OPS rules and forms. citeturn35search6turn18view0turn14view0turn21view0turn20view0

\- Preparation session completed 24 hours to 90 days prior; all required forms signed. citeturn35search6turn14view0turn18view0    
\- Transportation plan completed and excludes self-operated transportation. citeturn19view0turn35search2    
\- Safety and support plan completed; emergency contact documented; plan not modifiable during administration. citeturn19view1turn18view0    
\- Product potency information reviewed; client dose plan documented; maximum and session duration rules followed. citeturn15view1turn35search1turn21view3    
\- Administration session product transfer and end-of-session release forms completed; facilitator and client both comfortable; transport compliance confirmed. citeturn21view0turn19view0    
\- Adverse reactions documented as required; emergency services reporting duties met; post-session reactions tracked within 72 hours. citeturn20view0turn3search7

\#\# Voice of customer, FAQs, and search language map

This VoC synthesis uses a qualitative frequency rubric based on recurrence across official forms, consensus guidance, and high-activity public discussions. “High” means it appears consistently across multiple authoritative sources and/or repeated practitioner and patient discussions.

\#\#\# High-frequency practitioner and patient phrases

Ketamine clinic language    
\- “We monitor blood pressure, pulse ox, and heart rate.” citeturn33view0turn31view3turn36search0    
\- “You need a ride home, no driving after.” citeturn13view0turn31view1turn11view0    
\- “We track outcomes with PHQ-9 and GAD-7.” citeturn34search0turn34search5turn36search0    
\- “Blood pressure too high, we pause or stop.” citeturn33view0turn35search3turn36search8    
\- “Insurance usually doesn’t cover IV ketamine.” citeturn12search0turn12search1turn36search9

Oregon psilocybin facilitator language    
\- “Non-directive support, no diagnosis, no interpretation.” citeturn22view1turn36search7turn18view0    
\- “Transportation plan required, no driving after.” citeturn19view0turn18view0turn15view1    
\- “We have a safety and support plan and an emergency contact.” citeturn19view1turn18view0    
\- “Minimum session duration depends on dose.” citeturn35search1turn15view1turn21view3

\#\#\# Common FAQs that drive conversions and reduce cancellations

Patient-facing FAQs that clinics should answer early    
\- “What will you monitor during my session?” Patients commonly expect ECG leads, blood pressure cuff, and pulse oximetry in clinics. citeturn36search0turn33view0    
\- “How long do I have to stay after?” Esketamine is tied to at least 2 hours of observation under REMS, and ketamine infusion standards commonly require at least 1 hour post-infusion monitoring. citeturn5search4turn5search0turn33view0turn31view3    
\- “Do I have to stop benzodiazepines or other meds?” CANMAT cautions that benzodiazepines and other sedatives may interfere with response or worsen sedation. citeturn33view0    
\- “How many sessions will I need?” Patients commonly reference a 4 to 8 infusion induction course, which matches published consensus patterns. citeturn33view0turn30view0turn36search16    
\- “What about integration?” Patients and practitioners speak frequently about journaling, mindfulness, processing, and therapy add-ons. citeturn36search2turn36search6turn36search18

Provider-facing FAQs (B2B pain points)    
\- “What BP threshold do we use to pause?” CANMAT provides specific thresholds used in practice and cited in clinical discussions. citeturn33view0turn35search3    
\- “What can we bill?” Psychiatrists discuss limitations of psychotherapy add-on billing for racemic ketamine encounters, and time-based billing strategies. citeturn36search1turn36search5    
\- “How do we defend our protocol?” Sedation guideline alignment, SOPs, and quality improvement processes are core defensibility elements. citeturn8view0turn9view1turn13view0turn30view0

\#\#\# Keyword sets and hashtags for SEO and practitioner acquisition

Short-tail keywords    
Ketamine clinic: “ketamine infusion clinic,” “ketamine protocol,” “ketamine monitoring,” “ketamine blood pressure threshold,” “ketamine adverse events,” “ketamine billing codes,” “esketamine REMS monitoring.” citeturn33view0turn5search4turn12search2turn12search10    
Regulated psilocybin: “psilocybin facilitator,” “psilocybin client information form,” “psilocybin transportation plan,” “psilocybin administration session duration,” “psilocybin adverse reaction form.” citeturn14view0turn19view0turn35search1turn20view0turn22view1

Long-tail keywords    
\- “baseline blood pressure greater than 140/90 ketamine infusion not proceed” citeturn33view0turn35search11    
\- “pause ketamine infusion blood pressure 160/100 resume when below threshold” citeturn33view0turn35search3    
\- “ketamine infusion monitoring baseline midpoint endpoint 1 hour post infusion” citeturn33view0turn31view3    
\- “Oregon psilocybin preparation session 24 hours 90 days required forms” citeturn35search6turn18view0    
\- “Oregon psilocybin client information form lithium 30 days disqualify” citeturn14view0    
\- “Oregon psilocybin minimum duration administration session 35 mg to 50 mg six hours” citeturn35search1turn15view1    
\- “psilocybin facilitator non-directive approach meaning” citeturn22view1turn36search3    
\- “healing center administration session log includes dose type intended outcome” citeturn26view1

Hashtags    
Ketamine clinics: \#ketaminetherapy, \#ketamineinfusion, \#treatmentresistantdepression, \#measurementbasedcare, \#mentalhealthclinicoperations, \#revenuecyclemanagement. citeturn12search0turn33view0turn36search1    
Regulated psilocybin: \#psilocybinservices, \#psilocybinfacilitator, \#clientinformedconsent, \#harmreduction, \#nonDirectiveSupport, \#integration. citeturn18view0turn22view1turn21view0

\#\# Limits of public sources and legal and ethical constraints

Public data limits    
Many of the most operationally valuable details for clinics, such as exact staffing models, internal adverse-event analytics, payer contracting tactics, and proprietary integration protocols, are not publicly available. What is available tends to cluster into three buckets: consensus statements and guidelines, accreditation-style facility standards, and state regulatory forms and rules. citeturn13view0turn33view0turn30view0turn17view0turn26view1

Medical and legal scope constraints    
This report summarizes public guidance and regulations. It does not replace local law, licensure scope rules, institutional policies, or clinical judgment. Ketamine workflows involve controlled substance handling and medical risk. Psilocybin remains Schedule I federally, and state-regulated programs explicitly warn clients about federal status. citeturn27search1turn18view0turn15view1

Entheogenic religion operator constraints    
Federal religious exemptions for controlled substances involve RFRA-specific legal standards and DEA petitioning processes. The public record shows that the process exists but is challenging, and stakeholders report barriers to legal access and use under RFRA. Treat “legal protection and legitimacy” as a compliance program and legal strategy, not as a branding claim. citeturn2search5turn2search8turn2search6  


[image1]: <data:image/png;base64,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>

[image2]: <data:image/png;base64,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>